UroGen Pharma Valuation Multiples

UroGen Pharma Overview

About UroGen Pharma

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Founded

2004

HQ

Employees

235

Website

urogen.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $139M

EBITDA: ($106M)

EV

$892M

Valuation Multiples

Multiples.vc

Start free trial

UroGen Pharma Financials

UroGen Pharma reported last 12-month revenue of $139M and negative EBITDA of ($106M).

In the same LTM period, UroGen Pharma generated $124M in gross profit, ($106M) in EBITDA losses, and had net loss of ($133M).

UroGen Pharma P&L

In the most recent fiscal year, UroGen Pharma reported revenue of $110M and EBITDA of ($125M).

UroGen Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

UroGen Pharma Stock Performance

UroGen Pharma has current market cap of $890M, and enterprise value of $892M.

UroGen Pharma's stock price is $19.02.

UroGen Pharma Valuation Multiples

UroGen Pharma trades at 6.4x EV/Revenue multiple, and (8.4x) EV/EBITDA.

UroGen Pharma Financial Valuation Multiples

As of March 21, 2026, UroGen Pharma has market cap of $890M and EV of $892M.

Equity research analysts estimate UroGen Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

UroGen Pharma has a P/E ratio of (6.7x).

UroGen Pharma Margins & Growth Rates

UroGen Pharma's revenue in the last 12 month grew by 104%.

UroGen Pharma's revenue per employee in the last FY averaged $0.6M.

UroGen Pharma's rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

UroGen Pharma's rule of X is 184% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

UroGen Pharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

UroGen Pharma M&A Activity

UroGen Pharma acquired XXX companies to date.

Last acquisition by UroGen Pharma was on XXXXXXXX, XXXXX. UroGen Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

UroGen Pharma Investment Activity

UroGen Pharma invested in XXX companies to date.

UroGen Pharma made its latest investment on XXXXXXXX, XXXXX. UroGen Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).